Fintech PR
Synopsys Fusion Design Platform First to be Certified by Samsung Foundry for 5LPE Process with EUV Technology
- Samsung certified Synopsys Fusion Design Platform for 5LPE process technology using 64-bit Arm Cortex-A53 and Cortex-A57 processors
- Fusion Design Platform redefines conventional design tool boundaries to deliver full-flow better QoR and faster TTR, now for Samsung Foundry’s advanced 5LPE process
Synopsys, Inc. (Nasdaq: SNPS) today announced that Samsung Electronics has certified the Synopsys Fusion Design Platform
for Samsung’s 5-nanometer (nm) Low-Power Early (LPE) process with Extreme Ultraviolet (EUV) lithography technology. The AI-enhanced, cloud-ready Fusion Design Platform provides unprecedented full-flow quality-of-results (QoR) and time-to-results (TTR), enabling the full entitled performance and low power delivered by Samsung’s 5LPE process technology to accelerate the next wave of semiconductor designs, including high-performance computing (HPC), automotive, 5G, and artificial intelligence (AI) market segments.
“Through our 7-nanometer product shipment and the successful completion of 5-nanometer process development, we’ve proven our capabilities in EUV-based nodes. Using the Synopsys Fusion Design Platform, our mutual customers will be able to design the most competitive 5LPE SoC products for the full entitled performance and low power applications,” said JY Choi, vice president of Foundry Design Technology Team at Samsung Electronics. “Synopsys continues to be our vendor of choice for collaboration on new node development and enablement, so our foundry customers can confidently ramp their designs to volume production in all market segments, including automotive, AI, high-performance computing, and mobile.”
Samsung Foundry certified the Fusion Design Platform using the 64-bit Arm® Cortex®-A53 and Cortex-A57 processors, which are based on the Armv8 architecture. Key tools and features of the Synopsys Fusion Design Platform optimized for Samsung 5LPE process technology include:
- Fusion Compiler
RTL-to-GDSII Solution: Highly optimized full-flow support for latest 5LPE design rules delivering optimum design routability and convergence coupled to fastest TTR - IC Compiler II place-and-route: EUV single-exposure-based routing with optimized 5LPE design rule support, single fin variant-aware legalization, and via stapling to ensure maximum utilization while minimizing dynamic power
- Design Compiler® Graphical and Design Compiler NXT RTL synthesis: Correlation, congestion reduction, pin access-aware optimization, 5LPE design rule support, and physical guidance for IC Compiler II
- IC Validator physical signoff: Cloud-optimized physical signoff including DRC, LVS, and Fill. Innovative Explorer DRC and Live DRC technologies for enhanced productivity
- PrimeTime® timing signoff: Near-threshold ultra-low voltage variation modeling, via variation modeling, and placement rule-aware engineering change order (ECO) guidance
- StarRC parasitic extraction: EUV single pattern-based routing support, and new extraction technologies, such as coverage-based via resistance and vertical gate resistance modeling
- RedHawk Fusion: ANSYS RedHawk-driven EM/IR analysis and optimization within place-and-route
- Synopsys TestMAX DFT and Synopsys TestMAX ATPG test: FinFET-based, cell-aware, and slack-based transition testing for higher test quality
- Formality® equivalence checking: UPF-based equivalence checking with state transition verification
Synopsys’ Fusion Design Platform is in active production usage at market-leading companies; it redefines conventional design tool boundaries with the fusion of best-in-class optimization and industry-golden signoff and design-for-test (DFT) tools, enabling the most predictable full-flow convergence with the fewest iterations. The AI-enhanced platform boosts designer productivity by speeding up computation-intensive analyses and leverages past learning to achieve superior QoR. The Fusion Design Platform provides a streamlined cloud-ready design environment and is enabled on major public cloud providers’ and Synopsys-hosted infrastructure.
“Our long and successful collaboration with Samsung Foundry has enabled our mutual customers to adopt Synopsys’ market-leading solutions early, certified on Samsung’s most advanced node,” said Sassine Ghazi, general manager of Synopsys’ Design Group. “Combining the 5LPE benefits in power, performance, and gate density with the Synopsys Fusion Design Platform QoR and TTR advantages will enable our mutual customers to differentiate their next-generation products. Synopsys continues to focus on providing the best solutions for joint customers.”
SOURCE Synopsys, Inc.
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News4 days ago
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
-
Latest News4 days ago
Bitrue Gears Up for 2024 Bitcoin Halving with Trading Competition
-
Latest News5 days ago
Former Dreambox CEO Jessie Woolley-Wilson Joins Owl Ventures as Operating Partner
-
Latest News4 days ago
Global Airlines Appoints New Head of Finance from KPMG
-
Latest News4 days ago
BtcTurk Organizes Half Marathon in Istanbul to Celebrate Halving Period
-
Latest News4 days ago
Spendesk combines procurement with spend management through Okko acquisition
-
Latest News3 days ago
“The Hainan FTP and Me”: Looking at Hainan’s Transformations
-
Latest News5 days ago
99Bitcoins Reveals Website Revamp and Expansion Plans With Incentivized Learning Through Tokenization